Limits...
Application of Satkaryavada based on theory of Karya-Karana Vada.

Anupam A, Dwivedi RR - Ayu (2011)

Bottom Line: These were divided into two groups.In group "A" 26 patients were provided with haritaki tablet, while in group "B" 12 patients were provided with placebo tablets.In group "A" 7.69% of patients got complete relief, followed by 38.46% patients who got marked relief; 42.31% of patients got moderate relief, while 11.54% patients got mild relief.

View Article: PubMed Central - PubMed

Affiliation: Lecturer, Department of Basic Principles, Uttaranchal Ayurvedic College, Rajpur, Dehradun, Uttarakhand, India.

ABSTRACT
Cikitsa in Ayurveda is based on Karya-Karana Siddhanta. Satkaryavada is an independent view of Samkhyas regarding Karya-Karana. According to this principle, the Karya is present in Karana in subtle form before its manifestation. All the Karyas are possible only by the Sat Karana (existent cause). On this ground a hypothesis has been formulated and applied. The hypothesis was that since Karana is present in a drug it will perform the Karma. The clinical study was planned to study the Anulomana Karma of Haritaki in patients of Anaha. The drug was used in 38 patients. These were divided into two groups. In group "A" 26 patients were provided with haritaki tablet, while in group "B" 12 patients were provided with placebo tablets. In group "A" 7.69% of patients got complete relief, followed by 38.46% patients who got marked relief; 42.31% of patients got moderate relief, while 11.54% patients got mild relief. Group A showed highly significant results in comparison to group B.

No MeSH data available.


Related in: MedlinePlus

Relief in associated complaints in both the groups
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3361933&req=5

Figure 3: Relief in associated complaints in both the groups

Mentions: Group B: Placebo drug showed maximum 62.50% relief was observed in complaint of Mala Vibandha, followed by 50% relief found in the complaint of Katisula [Figure 3].


Application of Satkaryavada based on theory of Karya-Karana Vada.

Anupam A, Dwivedi RR - Ayu (2011)

Relief in associated complaints in both the groups
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3361933&req=5

Figure 3: Relief in associated complaints in both the groups
Mentions: Group B: Placebo drug showed maximum 62.50% relief was observed in complaint of Mala Vibandha, followed by 50% relief found in the complaint of Katisula [Figure 3].

Bottom Line: These were divided into two groups.In group "A" 26 patients were provided with haritaki tablet, while in group "B" 12 patients were provided with placebo tablets.In group "A" 7.69% of patients got complete relief, followed by 38.46% patients who got marked relief; 42.31% of patients got moderate relief, while 11.54% patients got mild relief.

View Article: PubMed Central - PubMed

Affiliation: Lecturer, Department of Basic Principles, Uttaranchal Ayurvedic College, Rajpur, Dehradun, Uttarakhand, India.

ABSTRACT
Cikitsa in Ayurveda is based on Karya-Karana Siddhanta. Satkaryavada is an independent view of Samkhyas regarding Karya-Karana. According to this principle, the Karya is present in Karana in subtle form before its manifestation. All the Karyas are possible only by the Sat Karana (existent cause). On this ground a hypothesis has been formulated and applied. The hypothesis was that since Karana is present in a drug it will perform the Karma. The clinical study was planned to study the Anulomana Karma of Haritaki in patients of Anaha. The drug was used in 38 patients. These were divided into two groups. In group "A" 26 patients were provided with haritaki tablet, while in group "B" 12 patients were provided with placebo tablets. In group "A" 7.69% of patients got complete relief, followed by 38.46% patients who got marked relief; 42.31% of patients got moderate relief, while 11.54% patients got mild relief. Group A showed highly significant results in comparison to group B.

No MeSH data available.


Related in: MedlinePlus